LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2Jeffrey D. Bradley, Mustafa Özgüroğlu, K.H. Lee et al.|ESMO Open|2024Cited by 74